登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Erythropoietin R】

Erythropoietin R信息

英文名称:Erythropoietin receptor
中文名称:促红细胞生成素受体
靶点别称
上市药物数量:82
临床药物数量:30
最高研发阶段:批准上市

Erythropoietin R产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
ACRO质量管理体系
 
评论(0)
 

Erythropoietin R 分子别名

EPOR

Erythropoietin R 分子背景

Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis , and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR pre-exists as dimers which upon binding of a 34 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor. Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors. EpoR signaling prevents neuronal death and ischemic injury.

Erythropoietin R 前沿进展

Erythropoietin R上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

Erythropoietin R临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定